Endocrine Abstracts

Pasireotide is the first pituitary-directed approved therapy for Cushing’s disease (CD), effective in reducing UFC >50% in about half of patients, and with a good tolerability profile but associated with a relatively high incidence of hyperglicemia. The aim of this study was to evaluate efficacy and safety of long-term treatment with pasireotide (PAS) in patients with CD. Methods: We retrospectively evaluated 17 consecutive patients (11 females) with CD treated with P...

Rationale: Pituitary neuroendocrine tumors (PitNets) are aggressive in 20% of cases, with local invasion, relapse/scarce response to conventional treatment, in the absence of reliable predictive parameters. In 2018, Trouillas et al. proposed a 5-tier prognostic classification, not widely validated yet. In our study we evaluated the outcomes of a PitNets monocentric series in the context of this classification.Materials & Methods: We retrospe...

Introduction: CyberKnife (CK) is an emerging treatment for pituitary tumours (PT) resistant to other therapies.Patients and methods: We report long-term CK effect on endocrine function and tumour volume in 20 PT patients (11M/10F, mean age 58.6±14.4years). Twelve patients harboured a non functioning adenoma, 2 an ACTH, 5 a GH (one case of TSH co-secretion) and 2 a PRL-secreting PT. Before CK nine patients had normal while 11 presented impaired pitui...